BACKStreptococcus thermophilus and its secreted molecules for the prevention of colorectal cancer
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 29 October 2021]
We are inviting expressions of interest (EoI) for commercializing “Streptococcus thermophilus and its secreted molecules for the prevention of colorectal cancer” technology. The innovation is developed by Professor WU Ka Kei, Professor of Department of Anaesthesia & Intensive Care of The Chinese University of Hong Kong (CUHK Reference: 18/MED/857).
The Technology
This invention disclosed a probiotic S. thermophilus and its secreted molecules and subsequently a method used for prevention of colorectal cancer. This invention will bring the consideration and rpactice of prevention of CRC by D. thermophilus or its secreted molescules to the primary healthcare scene by supporting their prevention effectiveness of CRC in an avidence-based approach.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Streptococcus thermophilus and its secreted molecules for the prevention of colorectal cancer
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 29 October 2021]
We are inviting expressions of interest (EoI) for commercializing “Streptococcus thermophilus and its secreted molecules for the prevention of colorectal cancer” technology. The innovation is developed by Professor WU Ka Kei, Professor of Department of Anaesthesia & Intensive Care of The Chinese University of Hong Kong (CUHK Reference: 18/MED/857).
The Technology
This invention disclosed a probiotic S. thermophilus and its secreted molecules and subsequently a method used for prevention of colorectal cancer. This invention will bring the consideration and rpactice of prevention of CRC by D. thermophilus or its secreted molescules to the primary healthcare scene by supporting their prevention effectiveness of CRC in an avidence-based approach.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Therapeutics
Erika Yuen
Office of Research and Knowledge Transfer Services
WU Ka Kei
YU Jun
N/A